Randomized trial evaluated skin health parameters in 66 women, suggesting ergothioneine improves aging signs.
Background: Ergothioneine (ergothioneine) is a naturally occurring antioxidant with emerging evidence supporting its role in cellular protection and anti-aging. However, clinical data on its cosmetic benefits remain limited. Objective: To evaluate the effects of daily oral supplementation with DR.ERGO® ergothioneine capsules on skin condition in healthy women reporting signs of skin aging. Methods: In this 8-week, randomized, double-blind, placebo-controlled trial, 66 women aged 35-59 years were assigned to receive either DR.ERGO® ergothioneine (30 mg/day) or placebo. Skin parameters including melanin index, erythema index, glossiness, elasticity (R2, R5, R7), spot count, wrinkle count were evaluated at baseline, 4 weeks, and 8 weeks. Results: Compared to placebo, the DR.ERGO® ergothioneine group showed significantly greater improvements in melanin and erythema reduction, skin glossiness, elasticity, and wrinkle and spot reduction (all p < 0.01). No adverse events were reported. Conclusion: Continuous oral intake of DR.ERGO® ergothioneine significantly improved skin aging parameters, with excellent safety and tolerability. These findings suggest DR.ERGO® ergothioneine may serve as an effective oral anti-aging agent.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: